Nutritional compositions comprising sn-1(3) monoacylglycerols for use in the treatment of growth delay in infants or children
A kind of nutritional composition, technology of monoacylglycerol, applied in lipid field
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0246] Table 1 below gives an example of the composition of an infant formula according to the invention. This composition is given by way of example only.
[0247] Table 1 : Examples of compositions of infant formulas according to the invention, eg formulas for premature infants
[0248]
[0249]
Embodiment 2
[0251] The concept was tested in a rat model of lipid maldigestion or malabsorption. use (ORLISTAT, tetrahydrolipstatin) to get a dyspepsia or malabsorption condition, Is a pancreatic lipase and gastric lipase inhibitor. For 21 days, rats were fed with a long-chain polyunsaturated fatty acid (LC-PUFA) supplement consisting mainly of eicosapentaenoic acid (EPA). Fish oil was used as a source of triacylglycerols and different EPA glycerides were evaluated: vanillin acetal of 2-EPA (from Stepan Lipid Nutrition Stepan Lipid Nutrition), 1,3 diacetyl- 2EPA (from Stepan Lipid Nutrition Stepan Lipid Nutrition) and sn-1(3)-MAG-EPA (available from Cognis GmbH, Germany).
[0252] Supplied at levels sufficient to reduce lipid absorption by 40% (ORLISTAT). will accept without (ORLISTAT) fish oil group was used as a positive control. Fatty acid profiles of erythrocyte lipids and plasma lipids were determined at different time intervals (D3, D7, D14 and D21). At the end of the ex...
Embodiment 3
[0257] This clinical study compared patients with Efficacy of sn-1(3) MAG and fish oil (TAG) to deliver EPA in humans with (ORLISTAT)-induced lipid dyspepsia disorder. Test comparisons were performed on volunteers who had treated to induce lipid dyspepsia or without (ORLISTAT) processing. The primary objective was to assess the accumulation of EPA in erythrocytes during a 21-day period of consumption as fish oil (TAG) or sn-1(3) MAG. Secondary objectives were to assess the accumulation of EPA in plasma over a 21-day period and to assess the pharmacokinetics of EPA after acute administration in the form of sn-1(3)MAG or TAG (AUC of chylomicrons at 10 hours postprandial ). see Figure 4 , which describes the clinical study timeline.
[0258] Table 2: Experimental groups
[0259]
[0260] Pharmacokinetic results ( Figure 5 ) shows that, compared to fish oil and (ORLISTAT) treatment with sn-1(3)MAG and (ORLISTAT) treatment produced an acute effect that was sta...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


